Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
SHANGHAI, April 23, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar have successfully passed the European United (EU) Good Manufacturing Practice (GMP) on-site inspectio...
Henlius successfully held its fourth Scientific Advisory Board (SAB) meeting
SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK, Henlius), a global biologics company specialized in the discovery and development of high-quality and affordable antibodies for the treatment of patients with cancer and autoimmune diseases, recently held its fourth ...
Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019
SHANGHAI, Nov. 7, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharmaceutical company inChina focusing on oncology and autoimmune diseases, won the award of "Biosimilar Initiative of the Year" (HLX01, rituximab injection) and was also shortlisted for the award of "t...
